[A18-03] Daratumumab (multiple myeloma) - Addendum to Commission A17-40
Last updated 15.02.2018
Project no.:
A18-03
Commission:
Commission awarded on 08.01.2018 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Haematology
Adults with multiple myeloma who have received at least one previous treatment
Combination with lenalidomide and dexamethasone or with bortezomib and dexamethasone: proof of considerable added benefit. Monotherapy: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A17-40 | Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-02-15 A G-BA decision was published.